The Elderly and Polypharmacy: What to Discontinue

We often receive elderly poly-medicated patients (with more than 10 different drugs) who ask us to reassess these prescriptions and, if possible, discontinue some drugs. The reasons are many: they forget to take it, mix up intakes or drugs, and of course, most often find it expensive. 

ticagrelor diabeticos

Statins are one of the most expensive drugs and when the patient has never presented a cardiovascular event (primary prevention) the temptation to discontinue can be irresistible. According to this study, statin discontinuation is a fatal mistake that might lead to a cardiovascular event in 1 every 3 patients with these characteristics. 

This analysis conducted by Dr. Philippe Giral and recently published in the European Heart Journal showed statin discontinuation is associated to 33% of cardiovascular risk in patients over 75 that take them as primary prevention. 


Read also: Soon after the EXCEL “Scandal” the NOBLE 5-year Outcomes Come Out: Mere Coincidence?


The study rationale is based on the fact that primary prevention with statins in patients over 75 has no evidence to support it but has a high cost for the healthcare system. 

This cohort of 120173 patients over 75 with no history of CAD had received statins for at least 2 years before inclusion and were followed up at mean 2.4 years. Discontinuation was defined as no drug intake for 3 consecutive months. 

During follow up, 14.3% discontinued statins and 4.5% were admitted for a major cardiovascular event. 


Read also: We Should Indicate More than 6 Months of DAPT in Lower Limb Disease.


Adjusted risk for statin discontinuation was 1.33 for any cardiovascular event, 1.46 for a coronary event, 1.26 for a cerebrovascular event and 1.02 (not significant) for vascular events. 

Conclusion

Statin discontinuation was associated to a 33% increased risk of cardiovascular events in elderly patients receiving medication in the context of primary prevention.

2020-01-10-ehz458-abierto

Original Title: Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France.

Reference: Philippe Giral et al. European Heart Journal (2019) 40, 3516–3525.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...